Needham & Company
-
Needham & Company Maintains a 'Hold' on Vertex (VRTX); Telaprevir Gets Enthusiastic Endorsement from FDA Advisory Committee, But Concerns Remain
-
Needham & Company Maintains a 'Hold' on Vertex (VRTX); Positive VX-770 Phase 3 Outcome in CF, But High Investor Expectations for HCV Program
-
Needham & Company Downgraded Vertex (VRTX) to Hold
-
Needham & Company Reiterates a 'Buy' on Vertex Pharmaceuticals (VRTX); Encouraging Top-Line Results from Phase 3 ADVANCE Trial
-
Needham & Company Reiterates a 'Buy' on Vertex Pharmaceuticals (VRTX); Room for Upside Around Phase 3 ADVANCE Results
-
Needham & Co Reiterates a 'Buy' on Vertex Pharmaceuticals (VRTX); Raises Price Target
-
Needham & Co Upgrades Vertex Pharmaceuticals (VRTX) to Buy
